Changing stroke rehab and research worldwide now.Time is Brain! trillions and trillions of neurons that DIE each day because there are NO effective hyperacute therapies besides tPA(only 12% effective). I have 523 posts on hyperacute therapy, enough for researchers to spend decades proving them out. These are my personal ideas and blog on stroke rehabilitation and stroke research. Do not attempt any of these without checking with your medical provider. Unless you join me in agitating, when you need these therapies they won't be there.

What this blog is for:

My blog is not to help survivors recover, it is to have the 10 million yearly stroke survivors light fires underneath their doctors, stroke hospitals and stroke researchers to get stroke solved. 100% recovery. The stroke medical world is completely failing at that goal, they don't even have it as a goal. Shortly after getting out of the hospital and getting NO information on the process or protocols of stroke rehabilitation and recovery I started searching on the internet and found that no other survivor received useful information. This is an attempt to cover all stroke rehabilitation information that should be readily available to survivors so they can talk with informed knowledge to their medical staff. It lays out what needs to be done to get stroke survivors closer to 100% recovery. It's quite disgusting that this information is not available from every stroke association and doctors group.

Wednesday, July 21, 2021

Coffee Study Casts More Doubt on Arrhythmia Link

More reasons for my 10-12 cups of coffee a day(1 pot, now decaf since caffeine is not the healthy part of coffee.). But don't do this, not proven as an antiarrhythmic. I'm doing my coffee habit for preventing dementia and Parkinsons.

Coffee Study Casts More Doubt on Arrhythmia Link

 

Can that cup of joe even be antiarrhythmic?

An overhead shot of a cup of coffee on a saucer on a heartbeat pattern formed from coffee grounds

Coffee drinkers, even those genetically predisposed to slower caffeine metabolism, were not at heightened risk of developing cardiac arrhythmias, a large cohort study found.

Instead, each cup of coffee was associated with a 3% lower risk of incident arrhythmia (adjusted HR 0.97, 95% CI 0.96-0.98) among U.K. Biobank participants with a mean follow-up of 4.5 years. Small reductions were observed for atrial fibrillation and/or flutter (HR 0.97, 95% CI 0.96-0.98) and supraventricular tachycardia (HR 0.96, 95% CI 0.94-0.99) in particular.

Additionally, a mendelian randomization study did not show that caffeine metabolism-related genes modify the relationship between coffee consumption and arrhythmias, reported Gregory Marcus, MD, MAS, of University of California San Francisco, and colleagues in JAMA Internal Medicine.

"These data suggest that common prohibitions against caffeine to reduce arrhythmia risk are likely unwarranted," the authors said. They noted that their results are in line with those of other recent studies showing no link between coffee consumption and increased tachyarrhythmias.

Marcus' group cited some potential mechanisms for coffee's observed antiarrhythmic effects in the study, namely its prolongation of left atrial effective refractory periods, blocking of adenosine receptors, antioxidant and anti-inflammatory properties, and catecholaminergic properties.

"Overall, the results ... strengthen the evidence that caffeine is not proarrhythmic, but they should not be taken as proving that coffee is an antiarrhythmic -- this distinction is of paramount importance," cautioned Zachary Goldberger, MD, MS, of University of Wisconsin-Madison, and Rodney Hayward, MD, of University of Michigan and the VA Ann Arbor Healthcare System.

"Health care professionals can reassure patients that there is no evidence that drinking coffee increases the risk for developing arrhythmias. This is particularly important for the many patients with benign palpitations who are devastated when they think, or are told, that they have to stop drinking coffee," according to their invited commentary.

The U.K. Biobank included more than 500,000 participants. Median coffee consumption was 2 cups per day, though 22.1% did not drink coffee.

Marcus and colleagues counted 386,258 people (mean age 56; 52.3% women; over 90% white) without a prior diagnosis of arrhythmia in their analysis.

People who drank more coffee were more likely to be older, white, and male. As a group, they also tended to report more peripheral artery disease, cancer, smoking, and alcohol drinking.

Study authors acknowledged that residual or unmeasured confounding could not be excluded given the observational nature of their study.

Another major caveat was their reliance on self-reported coffee intake at a single point in time. "Not only can this lead to recall bias, but subsequent and substantial changes in coffee consumption are also possible, including reductions due to new signs or symptoms (i.e., patients with palpitations may avoid coffee)," Goldberger and Hayward warned.

"Finally, it is important to recognize the distinction between coffee and caffeine. Caffeine is only one element of coffee, which contains other bioactive compounds such as diterpene alcohols and chlorogenic acids. As such, the mendelian randomization analysis is truly centered on caffeine, not coffee exposure," the editorialists added.

"The current study suggests that we can tell patients that waking up to a cup of coffee is not a dangerous ritual," they nevertheless maintained." However, it will be more important to listen to patients about their symptoms in association with coffee or caffeine exposure and engage in shared decision-making on an individual level."

  • author['full_name']

    Nicole Lou is a reporter for MedPage Today, where she covers cardiology news and other developments in medicine. Follow

Disclosures

The U.K. Biobank was established by the Wellcome Trust, the Medical Research Council, the U.K. Department of Health, and the Scottish Government.

Marcus disclosed receiving grants from Baylis, Medtronic, and Eight Sleep; consulting for Johnson & Johnson and InCarda; and holding equity in InCarda.

No comments:

Post a Comment